Sudden Late Onset of Clozapine-Induced Agranulocytosis

Austin State Hospital, Texas Department of Mental Health and Mental Retardation, Austin, USA.
Annals of Pharmacotherapy (Impact Factor: 2.06). 07/2002; 36(6):1012-5. DOI: 10.1345/aph.1A417
Source: PubMed


To report a patient who suddenly developed agranulocytosis after long-term clozapine therapy.
A 41-year-old white man suddenly developed agranulocytosis after 89 months of nearly continuous clozapine therapy. During this time, which included the addition of risperidone to the treatment regimen, his white blood cell (WBC) and granulocyte counts remained stable. One week after having stable hematologic counts, the patient suddenly developed agranulocytosis. WBC and granulocyte counts returned to baseline shortly after discontinuation of all medications and administration of sargramostim.
The main factor limiting the use of clozapine as a first-line agent in mentally ill patients is the risk of agranulocytosis. Although the greatest risk of developing this adverse reaction is during the initial 6-month exposure, clozapine-induced agranulocytosis continues to pose a risk after years of exposure. Current product labeling requires weekly WBC and granulocyte monitoring for the first 6 months of treatment with clozapine, which may be decreased to biweekly monitoring after 6 months. Based on the sudden and late onset of agranulocytosis in our patient, clinicians may consider opting for weekly monitoring of hematologic function for patients on long-term clozapine therapy. The likelihood that clozapine was the cause of the agranulocytosis was rated possible according to the Naranjo probability scale.
Clinicians must remain vigilant to trends in WBC and granulocyte counts and may wish to consider weekly hematologic monitoring regardless of duration of clozapine therapy. Patient and treatment system compliance with the registries' protocol regarding WBC monitoring is instrumental in reducing morbidity and mortality rates associated with clozapine use.

Download full-text


Available from: Tawny L Smith, Aug 31, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Clozapine is the gold standard and ‘last resort’ in treatment of refractory schizophrenia. It is important to know whether a trial with Clozapine is adequate or not. Six studies show a significantly higher response rate at Clozapine plasma trough levels above a therapeutic threshold of 350–400 µg/L. The absolute risk reduction is about 40%. An additional study found best results with plasma levels between 300 and 700 µg/L, and one (probably too small) study could not detect a significantly different response rate for 350–450 µg/L in comparison to 200–300 µg/L. In addition, two extension studies showed conversion from nonresponders to responders if plasma levels increased above the threshold. Investigations on time to response in treatment with Clozapine are often hampered by not controlling for time until plateau of dose titration or Clozapine concentration. One of the better studies found 34 responders within 8 weeks after the last dose escalation. The remaining 16 non-responding patients did not change their status during a mean follow-up of 75 weeks. A second 1 year trial found a superior differential response rate for Clozapine in comparison to haloperidol only during the first 6 weeks. A third study combined regular Clozapine plasma level assays with assessment of response status. At the time of response 17 out of 19 responders showed Clozapine concentrations above 350 µg/L. The nine nonresponders remained below this threshold throughout the rest of the year. These results favour an approach of raising the Clozapine plasma level in treatment-refractory schizophrenic patients who do not respond to an initial low-to-medium dose treatment with Clozapine. Some patients, especially young male smokers, will need dosages higher than 900 mg/day. Addition of low-dose fluvoxamine while closely monitoring Clozapine levels can help decrease the high number of necessary pills. An adequate trial with Clozapine should last at least 8 weeks on a plasma trough level above 350–400 µg/L.
    No preview · Article · Jun 2003 · Clinical Pharmacokinetics
  • [Show abstract] [Hide abstract]
    ABSTRACT: According to the recommended guidelines by Novartis, neutropenia in the range of a white blood cell count less than 3000 per mm, or an absolute neutrophil count (ANC) less than 1500 per mm, is classified as being in the 'red-alert zone' during clozapine treatment. If a patient's blood test result falls into this zone, immediate discontinuation of clozapine is recommended, and reinstitution is prohibited. However, in some patients, it is not entirely feasible to implement this standard guideline because of the lack of effective alternatives to clozapine treatment. Through retrospective chart reviews, five patients who had been maintained on clozapine treatment despite red-alert zone neutropenia were selected. The haematological and clinical courses of these patients were followed for more than 600 days and were compared with those of two control patients who discontinued clozapine due to neutropenia. In all five patients, no additional episodes of neutropenia occurred during the observation period despite continued clozapine treatment. However, three of them maintained a lower neutrophil count for the remaining observation period. Four patients responded favourably to clozapine treatment as judged by Clinical Global Impression score. Given the limitations of a retrospective chart review and the small number of patients, we cannot draw any definite conclusions. However, while the guidelines for the prevention of agranulocytosis should be generally followed, it may be that judicious continuation of clozapine treatment is less risk-prone than previously considered in selected cases where only a few feasible alternatives to clozapine are available. Moreover, there is an apparent necessity to develop new measures or methods that can differentiate between benign neutropenia and that leading to fatal agranulocytosis.
    No preview · Article · Apr 2004 · International Clinical Psychopharmacology

  • No preview · Article · Aug 2004 · Psychopharmakotherapie -Stuttgart-
Show more